NSC 23766

目录号:S8031

仅限科研使用

NSC 23766是一种Rac GTPase抑制剂,通过鸟嘌呤核苷酸因子(GEFs)靶向作用于Rac 活化,无细胞试验中IC50为~50 μM;但是不会抑制密切相关的靶点,Cdc42或RhoA。

NSC 23766 Chemical Structure

CAS: 1177865-17-6

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 1139.63 现货
RMB 901.16 现货
RMB 3849.78 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的NSC 23766发表文献78篇:

产品安全说明书

Rho抑制剂选择性比较

生物活性

产品描述 NSC 23766是一种Rac GTPase抑制剂,通过鸟嘌呤核苷酸因子(GEFs)靶向作用于Rac 活化,无细胞试验中IC50为~50 μM;但是不会抑制密切相关的靶点,Cdc42或RhoA。
靶点
Rac GTPase [1]
(Cell-free assay)
50 μM
体外研究

NSC23766被认为可以融入Rac1的表面沟槽,Rac1对GEF规格至关重要。NSC23766通过Rac特异性的GEF Trio或 Tiam1,有效地抑制Rac1结合和激活,这种作用具有剂量依赖性,通过其各自的GEFs,不干扰紧密相关的Cdc42或RhoA结合或激活。NSC23766有效调节细胞骨架中的Rac GTPase功能,和许多细胞功能,包括细胞周期,细胞生长,粘附,迁移和基因转录。NSC 23766 (50 μM)作用于NIH 3T3细胞,有效抑制血清或血小板衍生的生长因子诱导的Rac1激活和伪足形成,不影响内源性Cdc42或RhoA活性。NSC23766降低Trio 或 Tiam1而不是Vav, Lbc, Intersectin, 和组成型激活的Rac1突变型刺激的NIH 3T3细胞生长,也抑制Trio, Tiam1,或Ras诱导的细胞转化。NSC23766 抑制PC-3细胞增殖和锚定非依赖性生长,这种作用存在剂量依赖性。25 μM NSC23766抑制85%PC-3细胞侵袭穿过基底膜。[1]50 μM NSC 23766作用于人体血小板,抑制凝血酶诱导的Rac1和Rac2激活,以及血小板聚集。[2]NSC23766作用于swAPP-HEK293细胞,抑制Aβ40 和 Aβ42产生,不影响Notch 和 sAPPα。NSC23766 抑制细胞中γ-分泌酶活性,但是不是作为直接的γ-分泌酶抑制剂。NSC23766降低分泌的和细胞内的 Aβ40水平,IC50为48.94 μM,这种作用具有剂量依赖性。50 μM NSC 23766抑制57.97% Aβ42 释放。[3] NSC23766调节内皮NO合酶表达和内皮功能。100μM NSC23766抑制eNOS启动子活性,牛主动脉内皮细胞中抑制60%,bEND.3细胞中抑制30%至35%。NSC23766抑制Rac1,破坏eNOS mRNA稳定性,半衰期缩短到17小时。NSC23766 抑制ACh诱导的野生型小鼠主动脉环放松,这种作用存在剂量依赖性。[4]NSC23766抑制细胞生长,且诱导细胞凋亡。NSC23766降低MDA-MB-468和MDA-MB-231细胞活力,这种作用存在剂量依赖性, IC50 为~10 μM,与雌激素受体(ER),孕酮受体(PR),Her2,和p53基因突变状态无关。NSC23766对MCF12A正常乳腺上皮细胞的存活几乎没有影响。NSC 23766处理MDA-MB-231细胞24小时后,G1期细胞增长41%至65%,S和G2-M期随之减少。100 μM NSC23766诱导MDA-MB-468细胞凋亡增长6倍。NSC23766作用于乳腺癌细胞,抑制细胞周期停滞或凋亡,通过下调cyclin D1, survivin, X-连锁蛋白凋亡抑制剂(XIAP)而调节。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
RA4 NEHwcXpHfW6ldHnvckBCe3OjeR?= M37t[lUxKM7:TR?= NV\HepJpOjRiaB?= NXnDcYl4cW6qaXLpeJMhVWG2cnnn[YwhcW64YYPpc44> NH7LRnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[yNlMxQCd-MUe2NlI{ODh:L3G+
RA3 M{XKbGZ2dmO2aX;uJGF{e2G7 NV\lRmF2PTBizszN NHnSV5AzPCCq NFy3dFFqdmirYnn0d{BO[XS{aXflcEBqdn[jc3nvci=> NVTPSHhuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NlI{ODhpPkG3OlIzOzB6PD;hQi=>
RA2 NUDPXJdDTnWwY4Tpc44hSXO|YYm= M3;o[VUxKM7:TR?= MXKyOEBp Mki4bY5pcWKrdIOgUYF1emmpZXygbY53[XOrb36= NVHyeVNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2NlI{ODhpPkG3OlIzOzB6PD;hQi=>
RA1 Mn;aSpVv[3Srb36gRZN{[Xl? MmL3OVAh|ryP M1PPNVI1KGh? MmrzbY5pcWKrdIOgUYF1emmpZXygbY53[XOrb36= M{ewXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkKyN|A5Lz5zN{[yNlMxQDxxYU6=
RA-FLS (RA2)  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7uPJEzPS93MDFOwG0> NXXTVY5yOS17IHS= MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62IH3hco5meg>? M3zXS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NkKyN|A5Lz5zN{[yNlMxQDxxYU6=
IEC-6  MVPGeY5kfGmxbjDBd5NigQ>? NUWyd3ByOTJyINM1US=> MoXEOE83NzhiaB?= MmHYdJJmfmWwdIOgeIhmKGmwY4LlZZNm\CCjY4TpeoF1cW:wIH;mJGZCUyCjdDC2JIFv\CB6IHi= NIrscHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES0PFQ3OSd-MkC0OFg1PjF:L3G+
MDA-MB-231  NWG1Nm5yTnWwY4Tpc44hSXO|YYm= MUe1NE8yODBizszN NYHzbXNRPDhiaB?= MnTsbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHTlZ5Jm[XOnIHnuJJBpd3OyaH;yfYxifGmxbjDv[kBxPjVic4XieY5qfA>? NYfTb4g3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
MDA-MB-468 M{m1ZmZ2dmO2aX;uJGF{e2G7 MVi1NE8yODBizszN MVG0PEBp MVfpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1cW:wIH;mJJA3PSC|dXL1col1 NX3DfGw5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
MDA-MB-231  NHnKfotHfW6ldHnvckBCe3OjeR?= M1nYcVUxNzFyMDFOwG0> MWCyOEBp NHjXO45qdmO{ZXHz[ZMheGixc4Doc5J6dGG2aX;uJI9nKEqQSzDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXK2O2JyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
MDA-MB-468 MoPaSpVv[3Srb36gRZN{[Xl? MVu1NE8yODBizszN MVuyOEBp M3e5UYlv[3KnYYPld{BxcG:|cHjvdplt[XSrb36gc4YhUk6NIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NX21UpJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
MDA-MB-468 NGr1cYxHfW6ldHnvckBCe3OjeR?= NV;FVWVFOTByIN88US=> NUnnTII2OjRiaB?= NFW5WYtqdmirYnn0d:Kh[2G|cHHz[U0{KGGldHn2ZZRqd28EoB?= MmD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MDA-MB-468 MYPBdI9xfG:|aYOgRZN{[Xl? MkjvOVAwOTByIN88US=> MX:yOEBp MmjBbY5lfWOnczDhdI9xfG:|aYO= M4C1XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
T47D MX\GeY5kfGmxbjDBd5NigQ>? MnjJNVAxKM7:TR?= NF2weo01QCCq NGHjZm1qdmO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJIlvKEdzwrDwbIF{\SCjbnSg[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDpckBUKGGwZDDHNk1OKHCqYYPld:Kh NWnhb5plRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1NVU6PDBpPkKwOVE2QTRyPD;hQi=>
MCF7 NUTYSZI1TnWwY4Tpc44hSXO|YYm= NXPrdVRKOTByIN88US=> NFPuW5o1QCCq NXfjc|M3cW6lcnXhd4V{KHSqZTDj[YxtKG63bXLldkBqdiCJMdMgdIhie2ViYX7kJIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgbY4hWyCjbnSgS|IuVSCyaHHz[ZPDqA>? NF\KVFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
MDA-MB-231  MlOwSpVv[3Srb36gRZN{[Xl? M{KzTFExOCEQvF2= NIP2NoQ1QCCq NVLhUmZNcW6lcnXhd4V{KHSqZTDj[YxtKG63bXLldkBqdiCJMdMgdIhie2ViYX7kJIRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgbY4hWyCjbnSgS|IuVSCyaHHz[ZPDqA>? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0NEc,OjB3MUW5OFA9N2F-
MDA-MB-231 NXvHNXpnTnWwY4Tpc44hSXO|YYm= NWHjcI1LOC1zMECg{txO NHHGflYzPCCq NIW1dlR{\WynY4TpeoVtgSCrbnjpZol1eyCUYXOxJIFkfGm4YYTpc44hf2m2aH;1eEBqdnSncn\ldolv\yC5aYToJJRp\SCjY4Tpeol1gSCxZjD0bIUh[2yxc3XsfUBz\WyjdHXkJJNu[WyuIFfUVIF{\SCFZHO0Ni=> M{[5VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
MDA-MB-231 NXHIT4hRS3m2b4TvfIlkcXS7IFHzd4F6 NEi0dI8xNTFyMDFOwG0> NYfodWpPPDhiaB?= M3jhVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1XiZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUG1PVQxLz5{MEWxOVk1ODxxYU6=
MDA-MB-468 MYfDfZRwfG:6aXPpeJkhSXO|YYm= NWTTbZp[OC1zMECg{txO MmrqOFghcA>? MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGfpVWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWxOVk1OCd-MkC1NVU6PDB:L3G+
T47D MoLER5l1d3SxeHnjbZR6KEG|c3H5 NX\sWHI4OC1zMECg{txO NUXLR3F1PDhiaB?= M1rXc4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkHoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3MUW5OFAoRjJyNUG1PVQxRC:jPh?=
MCF7 Mk\HR5l1d3SxeHnjbZR6KEG|c3H5 NH;zbIoxNTFyMDFOwG0> MUK0PEBp NIf1bW1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODVzNUm0NEc,OjB3MUW5OFA9N2F-
SKBR3-pMKO.1 M{fGb2Z2dmO2aX;uJGF{e2G7 MWq1NEDPxE1? MX2yOEBp NGDxRllqdmirYnn0d{BT[WNzIHHjeIl3[XSrb36= NWXXcXFzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFM5OjVpPkKxPVQ{QDJ3PD;hQi=>
SKBR3 MV\GeY5kfGmxbjDBd5NigQ>? NVv3emg2PTBizszN NIrSdWEzPCCq NWH4Zop6cW6qaXLpeJMhWmGlMTDhZ5RqfmG2aX;u MmfJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEO4NlUoRjJzOUSzPFI2RC:jPh?=
NCI-H1703 NX3JRppkTnWwY4Tpc44hSXO|YYm= MYWwMVUxOCEQvF2= NF;DPZozPCCq NUHNPWQ4\GmvaX7pd4hmeyCkYYPhcEBPTi4QulKgZYN1cX[rdImg[I9{\SCmZYDlcoRmdnSuedMg MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjV2OUG2NEc,OjJ3NEmxOlA9N2F-
NCI-H1703 MVLGeY5kfGmxbjDBd5NigQ>? NEHWPYEyODBizsznM41t NEX5dWYzPCCq M1ju[5Ntd3e|IIDyc4dz\XO|aX;uJJRpem:3Z3igeIhmKEdzwrDwbIF{\SCxZjD0bIUh[2WubDDjfYNt\Q>? MnPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEmxOlAoRjJ{NUS5NVYxRC:jPh?=
NCI-H1703 NFq0fZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rMVVAuPTByIN88US=> MoLoNlQhcA>? MnTubY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3m3blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUS5NVYxLz5{MkW0PVE3ODxxYU6=
T98MG NG[0Z3JHfW6ldHnvckBCe3OjeR?= MWS1NEBuVQ>? MYSyOEBp MXrEUXNQ NXPmWGg{\W6qYX7j[ZMhfGinIHHueIlucWe{YYTvdpkh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NHPScHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izNlEzOCd-MkO4N|IyOjB:L3G+
A172MG NY\XfnV2TnWwY4Tpc44hSXO|YYm= M3;UU|UxKG2P NXnSVpZmOjRiaB?= MXjEUXNQ MkTR[Y5p[W6lZYOgeIhmKGGwdHntbYdz[XSxcomg[YZn\WO2IH;mJIVzdG:2aX7pZi=> MomwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6M{KxNlAoRjJ|OEOyNVIxRC:jPh?=
U87MG MWfGeY5kfGmxbjDBd5NigQ>? NWDGZppIPTBibV2= MkjxNlQhcA>? NGDCc3hFVVOR MYnlcohidmOnczD0bIUh[W62aX3p[5JifG:{eTDl[oZm[3Rib3[g[ZJtd3Srbnni M4i0TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OEOyNVIxLz5{M{izNlEzODxxYU6=
PC40 NGe2eoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFfRVY02OCCvTR?= MWqxOFQhcA>? M3vxVmROW09? M1TyUoV5cGmkaYTzJJN6dmW{Z3nzeIlkKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeJMh[2:vYnnu[YQhfHKnYYTt[Y51KHerdHig[ZJtd3SrbnnixsA> NUTsNJFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4N|IyOjBpPkKzPFMzOTJyPD;hQi=>
PC38 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MY[1NEBuVQ>? Mk\LNVQ1KGh? NEfrT49FVVOR NI\5TIRmgGirYnn0d{B{gW6ncnfpd5Rq[yCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGOxbXLpcoVlKHS{ZXH0cYVvfCC5aYToJIVzdG:2aX7pZuKh NIr1XmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izNlEzOCd-MkO4N|IyOjB:L3G+
T98MG MmjYR4VtdCCYaXHibYxqfHliQYPzZZk> MUW1NEBuVQ>? MlHONVQ1KGh? MkThSG1UVw>? MVHlfIhq[mm2czDzfY5memerc4TpZ{BidnSrcILvcIln\XKjdHn2[UBm\m[nY4TzJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHXycI91cW6rYtMg NXfBZYFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4N|IyOjBpPkKzPFMzOTJyPD;hQi=>
A172MG MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGnCRmI2OCCvTR?= NYnsc44yOTR2IHi= MoHvSG1UVw>? NXLLdnV1\XiqaXLpeJMhe3mwZYLnbZN1cWNiYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1eyClb33ibY5m\CC2cnXheI1mdnRid3n0bEBmemyxdHnubYLDqA>? NESwTXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izNlEzOCd-MkO4N|IyOjB:L3G+
U87MG M3m0Z2NmdGxiVnnhZoltcXS7IFHzd4F6 NVXyN4tWPTBibV2= NUe3dmxMOTR2IHi= MVLEUXNQ MUTlfIhq[mm2czDzfY5memerc4TpZ{BidnSrcILvcIln\XKjdHn2[UBm\m[nY4TzJINwdWKrbnXkJJRz\WG2bXXueEB4cXSqIHXycI91cW6rYtMg NFfXeG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{izNlEzOCd-MkO4N|IyOjB:L3G+
Ki-67+ CLL MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\EOVAhyrWP NIPZfIQ2KGR? MY\k[YNz\WG|ZYOgeIhmKG63bXLldkBw\iCNaT22O{vDqEOOTDDj[Yxtew>? NVjkR254RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFEzOTdpPkK0OVAyOjF5PD;hQi=>
NIH3T3  NVn0WlJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHDdIIxOTByIN88US=> NYDxSG85OjUEoHi= MVjoZZMhdm9ic3nncolncWOjboSgbY1x[WO2IH;uJINmdGxidnnhZoltcXS7 MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB|N{C2NEc,OjVyM{ewOlA9N2F-
U2-OS NF3IWGVHfW6ldHnvckBCe3OjeR?= NV[2OZIyOTByIN88US=> NYriTmdvOjRiaB?= NIHTNpVFVVOR NF[zcHVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNUBxcGG|ZdMg MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUOyO{c,OjVzMEmzNlc9N2F-
SW480  NFX2N3ZHfW6ldHnvckBCe3OjeR?= M{DpVlExOCEQvF2= MWWyOEBp MVXEUXNQ MUHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMTDwbIF{\cLi M2e3O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N|I4Lz5{NUGwPVMzPzxxYU6=
A431 MmDVSpVv[3Srb36gRZN{[Xl? NH\vdnUyODBizszN MXmyOEBp NVXNNY0{TE2VTx?= NVTzS2U6cW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBqdiC2aHWgS|EheGijc3ZCpC=> NWi4[G1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNFk{OjdpPkK1NVA6OzJ5PD;hQi=>
U2-OS NGnGVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rMZlExOCEQvF2= NVfy[Vh4OjRxNEivO|IhcA>? M1HYR4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOUOyO{c,OjVzMEmzNlc9N2F-
SW480  MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWxNFAh|ryP MUeyOE81QC95MjDo MkWybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M{TnO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N|I4Lz5{NUGwPVMzPzxxYU6=
A431 NUL4ZoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXzNVAxKM7:TR?= M{e5N|I1NzR6L{eyJIg> NYnPRmZmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M1HIN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUC5N|I4Lz5{NUGwPVMzPzxxYU6=
RBMECs MkX2SpVv[3Srb36gRZN{[Xl? MW[xNFAh|ryPwrC= Ml3PN|DDqG2rbh?= M1zpcYJtd2OtZYOgOmJvgi2lQV3QMY1m\GmjdHXkJIFkfGm4YYTpc44hd2ZiUnHjNUBqdiCHTVHQMWlKNXS{ZXH0[YQhWkKPRVPz NYixdllSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVgxOzlpPkK2N|U5ODN7PD;hQi=>
human aortic smooth muscle cells NFPvb5FHfW6ldHnvckBCe3OjeR?= MVe1NEB2VQ>? MU\Jcohq[mm2aX;uJI9nKFKjY{GgZolv\GmwZzD0c{BR[WtzIHnuJIh2dWGwIHHvdpRq[yC|bX;veIghdXW|Y3zlJINmdGy|IHH0JFUxKHWPIHL5JHNFWy2SQVfFJIJie2WmIHPo[Y1qdHWvaX7ld4NmdmOn MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV{N{CzNkc,OTl3MkewN|I9N2F-
human aortic smooth muscle cells NYjteIZTTnWwY4Tpc44hSXO|YYm= M2L1[FExOCEQvF2= NGjRXmdKdmirYnn0bY9vKG:oIGLhZ|Eh[mmwZHnu[{B1dyCSYXuxJIlvKGi3bXHuJIFwenSrYzDzcY9wfGhibYXzZ4xmKGOnbHzzJIF1KDFyMDD1UUBjgSCVRGOtVGFITSCkYYPl[EBkcGWvaXz1cYlv\XOlZX7j[S=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV{N{CzNkc,OTl3MkewN|I9N2F-
Assay
Methods Test Index PMID
Western blot pCREB / CREB OCT4 / SOX2 / Nanog active Rac1 / Rac1 25319697 31338333
Immunofluorescence IP3K-A / F-actin BART / Rac1 19890013 22745590
体内研究 NSC23766诱导造血干细胞/前体细胞动员。NSC23766按2.5 mg/kg剂量腹腔注射到驱动不良的C57Bl/6小鼠品系,注射6小时后,导致循环中的造血干细胞/前体细胞增强2倍。[2]NSC23766处理小鼠,减轻脂多糖诱导的急性肺损伤。NSC23766按1或3 mg/kg剂量处理,不仅降低炎性细胞浸润和MPO活性,也抑制促炎介质,和肿瘤坏死因子-α,白细胞介素-1β,mRNA表达。NSC23766也降低Evans Blue和清蛋白在LPS处理的肺部积累。[6]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
  • Rho GTPase活性测定:

    10-cm培养皿中的对数生长期细胞生长在0.5%血清培养基中饥饿处理24小时,然后溶解在含20 mM Tris HCl (pH 7.6), 100 mM NaCl, 10 mM MgCl2, 1% Nonidet P-40, 10% 甘油, 和1×蛋白酶抑制剂混合物的Buffer中。澄清裂解液,蛋白浓度归一化,通过效应结构域下拉检测测量裂解液中与GTP结合的Rac1。His6-PAK1 PBD拉下实验中,E. coli纯化的Ni2+-琼脂糖固定的His6-PAK1 PBD域与细胞裂解液温育30分钟。使用anti-Rac1单克隆抗体,通过免疫印迹,在洗涤缓冲液中洗涤两次Ni2+琼脂糖共同沉淀。

细胞实验:[5]
  • Cell lines: 人类乳腺癌细胞 MDA-MB-468
  • Concentrations: 0-100 μM
  • Incubation Time: 2 天
  • Method: 细胞按1.5×104个/mL接种在96孔组织培养板中,孔中含200 μL培养基。 接种24小时后, 使用含指定浓度NSC23766的 200 μL新鲜培养基置换原来的培养基。处理末期,每孔加入20 μL MTS 溶液,在37°C下温育2小时。在96孔板酶标仪上读取490 nm处吸光值。

溶解度(25°C)

体外

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 530.96
化学式

C24H35N7.3HCl

CAS号 1177865-17-6
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们
Tags: buy NSC23766|NSC23766 ic50|NSC23766 price|NSC23766 cost|NSC23766 solubility dmso|NSC23766 purchase|NSC23766 manufacturer|NSC23766 research buy|NSC23766 order|NSC23766 mouse|NSC23766 chemical structure|NSC23766 mw|NSC23766 molecular weight|NSC23766 datasheet|NSC23766 supplier|NSC23766 in vitro|NSC23766 cell line|NSC23766 concentration|NSC23766 nmr|NSC23766 in vivo|NSC23766 clinical trial|NSC23766 inhibitor|NSC23766 Cell Cycle inhibitor